Results 11 to 20 of about 101,187 (179)

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]

, 2020
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin, Eskander, Ramez, Glenn, Sean T, Goodman, Aaron, Ikeda, Sadakatsu, Kato, Shumei, Kumaki, Yuichi, Kurzrock, Razelle, Lee, Suzanna, Lenzo, Felicia L, Morrison, Carl, Nikanjam, Mina, Okamura, Ryosuke, Papanicolau-Sengos, Antonios   +13 more
core   +1 more source

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

BMC Cancer, 2019
Background Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases.
Mark T. J. van Bussel, Jos H. Beijnen, Dieta Brandsma   +2 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer

ESMO Open, 2019
Background Nivolumab showed a survival benefit for advanced gastric cancer (AGC). However, an acceleration of tumour growth during immunotherapy, (hyperprogressive disease, HPD) has been reported in various cancers.
Masahiko Aoki, Hirokazu Shoji, Kengo Nagashima, Hiroshi Imazeki, Takahiro Miyamoto, Hidekazu Hirano, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Kazuhide Higuchi, Narikazu Boku   +12 more
doaj   +1 more source

New-onset insulin-dependent diabetes due to nivolumab

Endocrinology, Diabetes & Metabolism Case Reports, 2018
Nivolumab, a monoclonal antibody against programmed cell death-1 receptor, is increasingly used in advanced cancers. While nivolumab use enhances cancer therapy, it is associated with increased immune-related adverse events.
Ali A Zaied, Halis K Akturk, Richard W Joseph, Augustine S Lee   +3 more
doaj   +1 more source

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting

Translational Oncology, 2020
We aimed to identify the clinical characteristics related to increased nivolumab exposure in Japanese patients with renal cell carcinoma (RCC) in real-world clinical setting.
Renpei Kato, Daiki Ikarashi, Tomohiko Matsuura, Shigekatsu Maekawa, Yoichiro Kato, Mitsugu Kanehira, Ryo Takata, Rie Tokuyama, Kanako Tamai, Naoto Harigai, Yukoh Nakazaki, Wataru Obara   +11 more
doaj   +1 more source

An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors [PDF]

, 2019
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium ...
Au, L, Chauhan, D, Edmonds, K, Gore, M, Hughes, P, Husson, O, Lai, Z, Larkin, J, Lingard, K, Ludlow, A, Lynch, J, Mann, J, Mclean, E, O'Reilly, A, Pattison, N, Teh, JJ, Turajlic, S, Wiseman, T   +17 more
core   +3 more sources

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one [PDF]

, 2018
In renal cancer emerging treatment options are becoming available and there is a strong need to combine therapies to reformulate and adjourn clinical practice.
Botticelli, A., Marchetti, P., Nuti, M., Rughetti, A., Zizzari, I. G.   +4 more
core   +1 more source

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

Frontiers in Oncology, 2021
BackgroundNivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after sorafenib failure.
Yuan-Hung Kuo, Yi-Hao Yen, Yen-Yang Chen, Kwong-Ming Kee, Chao-Hung Hung, Sheng-Nan Lu, Tsung-Hui Hu, Chien-Hung Chen, Jing-Houng Wang   +8 more
doaj   +1 more source

Multi-institutional report on toxicities of concurrent nivolumab and radiation therapy

Advances in Radiation Oncology, 2018
Purpose: Radiation therapy (RT) and nivolumab are standard therapies for a wide range of advanced and metastatic cancers, yet little is known about the toxicity profile of their combined treatment.
Neha P. Amin, MD, Maliha Zainib, BS, Sean M. Parker, BS, Manuj Agarwal, MD, Malcolm D. Mattes, MD   +4 more
doaj   +1 more source